- Bowtell, David D;
- Böhm, Steffen;
- Ahmed, Ahmed A;
- Aspuria, Paul-Joseph;
- Bast, Robert C;
- Beral, Valerie;
- Berek, Jonathan S;
- Birrer, Michael J;
- Blagden, Sarah;
- Bookman, Michael A;
- Brenton, James D;
- Chiappinelli, Katherine B;
- Martins, Filipe Correia;
- Coukos, George;
- Drapkin, Ronny;
- Edmondson, Richard;
- Fotopoulou, Christina;
- Gabra, Hani;
- Galon, Jérôme;
- Gourley, Charlie;
- Heong, Valerie;
- Huntsman, David G;
- Iwanicki, Marcin;
- Karlan, Beth Y;
- Kaye, Allyson;
- Lengyel, Ernst;
- Levine, Douglas A;
- Lu, Karen H;
- McNeish, Iain A;
- Menon, Usha;
- Narod, Steven A;
- Nelson, Brad H;
- Nephew, Kenneth P;
- Pharoah, Paul;
- Powell, Daniel J;
- Ramos, Pilar;
- Romero, Iris L;
- Scott, Clare L;
- Sood, Anil K;
- Stronach, Euan A;
- Balkwill, Frances R
High-grade serous ovarian cancer (HGSOC) accounts for 70-80% of ovarian cancer deaths, and overall survival has not changed significantly for several decades. In this Opinion article, we outline a set of research priorities that we believe will reduce incidence and improve outcomes for women with this disease. This 'roadmap' for HGSOC was determined after extensive discussions at an Ovarian Cancer Action meeting in January 2015.
